Drug intelligence / Profile preview

NanaBis (Medlab Clinical, 2a9e23)

Development stage
Phase 3
Lead developer
Medlab Group
Modality
Small Molecules
Administration
Oromucosal
01

Overview

NanaBis is a proprietary cannabinoid-based pharmaceutical formulation developed for medical use, particularly in the management of pain. It is an oromucosal spray containing a 1:1 ratio of tetrahydrocannabinol (THC) and cannabidiol (CBD), both derived from cannabis. The mechanism of action involves THC acting as a partial agonist at the cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2), leading to modulation of neurotransmitter release, analgesia, and other central nervous system effects. CBD acts as an antagonist or modulator at these receptors and also interacts with other targets such as serotonergic receptors and vanilloid receptors, contributing to its therapeutic profile. NanaBis has been investigated primarily for cancer-related pain but may have potential applications in other chronic pain conditions.

Brand names
NanaBis
Other names
THC:CBD 1:1 oro-buccal sprayd9-THC & CBD formulation
02

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on NanaBis (Medlab Clinical, 2a9e23).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NanaBis (Medlab Clinical, 2a9e23).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call